Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:22 16/07/2024 pm IST			5-day change	1st Jan Change
13.1 ^GBX	-2.60%		-5.07%	+44.75%

02/07	Poolbeg Pharma PLC Announces Change of Registered Address	CI
01/05	Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	MT

Poolbeg Pharma upbeat on preliminary influenza drug results

January 09, 2023 at 07:33 pm IST

(via NewsDirect)

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Poolbeg Pharma PLC

Poolbeg Pharma PLC Announces Change of Registered Address	02/07	CI
Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	01/05	MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	01/05	AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	01/05	CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	30/04	MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	30/04	AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	30/04	MT
Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2023	30/04	CI
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	20/03	AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update	20/03	CI
Diversified Energy offers dividend alternative	15/02	AN
Poolbeg Pharma's Nonexecutive Chair Transitions to Executive Role	15/02	MT
Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman	15/02	CI
Katoro Gold launches fundraising, eyes board shake-up	13/02	AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	12/02	CI
Poolbeg Pharma Therapy Shows Efficacy in Lowering Cancer Immunotherapy-induced Cytokine Release Syndrome	17/01	MT
Poolbeg Pharma hails POLB 001'S potential to treat CRS	17/01	AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	17/01	CI
K3 Business says cash balances ahead of forecast	21/12	AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	20/12	CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	11/12	CI
Poolbeg Pharma plc Announces Directorate Changes	30/11	CI
Poolbeg hails approval; EDX links with Thermo Fisher	21/11	AN
Poolbeg Pharma appoints former Amryt executives to team	09/11	AN
Poolbeg Pharma Names Business, Legal Chiefs	09/11	MT

Chart Poolbeg Pharma PLC

Duration

Period

More charts

Company Profile

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Sector

Biotechnology & Medical Research

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1345 GBP

Average target price

0.21 GBP

Spread / Average Target

+56.13%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
POOLBEG PHARMA PLC	+44.75%	8.73Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.40%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.15%	12TCr
ARGENX SE	+25.44%	2.77TCr
BIONTECH SE	-18.48%	2.03TCr
GENMAB A/S	-15.17%	1.68TCr
BEIGENE, LTD.	-16.30%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+12.78%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.46TCr
SAREPTA THERAPEUTICS, INC.	+56.97%	1.44TCr

Bio Therapeutic Drugs